KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Share-based Compensation (2016 - 2025)

Pfizer (PFE) has disclosed Share-based Compensation for 17 consecutive years, with $225.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed N/A to $225.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $799.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $799.0 million for FY2025, 8.89% down from the prior year.
  • Share-based Compensation for Q4 2025 was $225.0 million at Pfizer, up from $201.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $700.0 million in Q3 2024, with the low at $86.0 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $259.4 million, with a median of $203.0 million recorded in 2025.
  • The sharpest move saw Share-based Compensation skyrocketed 363.58% in 2024, then crashed 71.29% in 2025.
  • Over 5 years, Share-based Compensation stood at $686.0 million in 2021, then fell by 25.95% to $508.0 million in 2022, then crashed by 76.18% to $121.0 million in 2023, then skyrocketed by 478.51% to $700.0 million in 2024, then plummeted by 67.86% to $225.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $225.0 million, $201.0 million, and $203.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.